连续干血斑C肽采样可检测新发1型糖尿病β细胞功能早期保留
USTEKID试验比较了尿C肽/肌酐比(UCPCR)和干血斑(DBS)C肽与混合餐耐量试验(MMTT)在评估β细胞功能中的表现,发现DBS曲线下面积在12个月内持续下降,且干预组在第20周时下降显著小于对照组,而UCPCR无此差异。结论提示频繁采样的葡萄糖校正DBS比MMTT更敏感,可作为家庭β细胞功能标志物。
要点
- DBS C肽在干预组第20周即显示下降显著小于对照组,比MMTT更早发现差异。
- UCPCR在干预早期未见变化,不能替代MMTT用于早期β细胞功能评估。
- 6个月DBS数据可预测对照组12个月MMTT C肽,但干预组预测不成立。
核心结论
- 频繁采样的葡萄糖校正DBS比MMTT更敏感地反映早期β细胞功能变化,可作为家庭监测标志物。
研究设计与样本
- 在USTEKID干预试验中,于筛查时及第28、52周行2小时MMTT,并在MMTT后采集UCPCR,同时每周采集空腹和餐后60分钟DBS至第28周,之后每月至第52周。
- 比较UCPCR和葡萄糖校正DBS结果与MMTT结果,并采用混合线性模型、bootstrap单样本t检验和自回归积分移动平均分析组间差异。
主要发现
- UCPCR在最初6个月无变化,至12个月才下降;MMTT C肽则不同。
- DBS 0-60分钟曲线下面积在12个月内稳步下降。
- 干预组DBS C肽下降在第20周时显著小于对照组(P < 0.05),而UCPCR未显示此差异,MMTT至52周才显现。
- 6个月DBS斜率可预测对照组12个月MMTT C肽,但不能预测干预组,与干预效果从6至12个月增强一致。
临床怎么用
- DBS采样可考虑作为新发1型糖尿病临床试验中β细胞功能的家庭监测替代方案。
- UCPCR不适用于干预早期β细胞功能变化的检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether less invasive C-peptide tests, urine C-peptide-to-creatinine ratio (UCPCR) and dried blood spot (DBS), could replace the mixed-meal tolerance test (MMTT) in the context of an interventional clinical trial (Ustekinumab in Adolescents With Recent-Onset Type 1 Diabetes [USTEKID]). RESEARCH DESIGN AND METHODS: C-peptide was assessed at screening and weeks 28 and 52 using a 2-h MMTT. UCPCR samples were taken after each MMTT. Fasting and 60-min postmeal DBS samples were collected weekly to week 28 and then monthly to week 52. UCPCR and glucose-adjusted DBS results were compared with MMTT results. Weekly DBS averages were calculated and differences between treatment groups assessed using a mixed linear model, bootstrap one-sample t tests, and autoregressive integrated moving averages. Six months of weekly DBS data were used to predict 12-month C-peptide levels. RESULTS: Unlike MMTT C-peptide, UCPCR did not change in the first 6 months, before decreasing by 12 months. The DBS area under the curve from 0 to 60 min declined steadily over 12 months. The DBS C-peptide decline in the intervention group was significantly less than that in the control group by week 20 (P < 0.05). This was not apparent with UCPCR and did not become evident until 52 weeks with MMTT. The slope from 6 months of DBS could predict 12-month MMTT C-peptide in the control but not in the intervention group, consistent with the increasing impact of the intervention from 6 to 12 months indicated by the MMTT data. CONCLUSIONS: Frequently sampled glucose-adjusted DBS was more sensitive to early change than MMTT and could serve as a home-based marker of β-cell function, whereas UCPCR was not sensitive to change in the early period.
引用
- Dunseath GJ, Cheung WY, Luzio SD, et al. Serial Dried Blood Spot C-Peptide Sampling, but Not Urine C-Peptide-to-Creatinine Ratio, Detects Early Preservation of β-Cell Function in New-Onset Type 1 Diabetes: Experience From the USTEKID Trial. Diabetes Care. 2026. PMID: 42118600. doi:10.2337/dc25-2896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。